Genus plc (GNS) AI Stock Analysis

• Market Cap: £1.66B
• Dividend Yield: 1.27%
• Average Volume (3M): 125.83K
• Price to Earnings (P/E): 85.9
• Beta (1Y): 1.90
• Revenue Growth: 0.60%
• EPS Growth: 142.98%
• Country: UK
• Employees: 3,500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.27
• Shares Outstanding: 66,537,450
• 10 Day Avg. Volume: 160,199
• 30 Day Avg. Volume: 125,825
• PEG Ratio: 0.49
• Price to Book (P/B): 2.83
• Price to Sales (P/S): 2.00
• P/FCF Ratio: 27.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £2,700.00
• Price Target Upside: 7.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 71 Outperform
• Price Target: 2,967.00p ▲(17.97% Upside)

Genus plc's overall stock score is driven by strong financial performance and positive technical indicators. The company's strategic progress and optimistic outlook from the earnings call further support the score. However, a high P/E ratio suggests potential overvaluation, which tempers the overall assessment.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, enhancing long-term financial stability.

Strategic Initiatives

The Value Acceleration Program's success in improving cash flow and inventory management strengthens operational efficiency and profitability.

FDA Approval Progress

Progress towards FDA approval for PRRS Resistant Pig could open new markets and enhance competitive advantage in genetic innovation.

Negative Factors

Profitability Margins

Low net profit margins may limit the company's ability to reinvest in growth initiatives, affecting long-term financial health.

Cash Flow Volatility

Volatile free cash flow can constrain the company's ability to fund new projects or manage debt, posing risks to financial stability.

FX Headwinds

Foreign exchange headwinds can erode earnings and reduce competitiveness in international markets, impacting profitability.

Genus plc Business Overview & Revenue Model

Company Description

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in reproductive, and other technical services to farmers. Genus plc has a strategic collaboration with Beijing Capital Agribusiness Co. Ltd to pursue the porcine reproductive respiratory syndrome virus resistant regulatory and development work in China. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

How the Company Makes Money

Genus generates revenue through several key streams. Primarily, the company earns money from the sale of genetic materials, such as semen and embryos, to livestock producers. These products are essential for breeding programs aimed at improving animal traits such as growth efficiency, disease resistance, and reproductive performance. Additionally, Genus offers genetic services, including data analysis and breeding consultancy, which provide added value to their customers. Significant partnerships with agricultural producers and cooperatives enhance Genus's market reach and contribute to its earnings. The company also benefits from research and development investments that lead to innovation in genetic technologies, ensuring a competitive edge in the animal breeding industry.

Genus plc Financial Statement Overview

Summary

Genus plc shows strong revenue growth and operational efficiency, supported by a solid balance sheet. However, profitability margins and cash flow stability present areas for improvement.

Income Statement

Genus plc has demonstrated consistent revenue growth over the years, with a notable increase in the latest period. The gross profit margin is strong, indicating efficient cost management. However, the net profit margin is relatively low, suggesting potential areas for cost optimization or revenue enhancement. The EBIT and EBITDA margins are healthy, reflecting good operational efficiency.

Balance Sheet

The company's debt-to-equity ratio is moderate, indicating a balanced approach to leveraging. Return on equity has seen some fluctuations but remains positive, suggesting that the company is generating returns on shareholders' investments. The equity ratio is stable, showing a solid capital structure.

Cash Flow

Genus plc's cash flow from operations is robust, but free cash flow has experienced volatility, which could impact future investments or debt repayments. The operating cash flow to net income ratio is healthy, indicating good cash generation relative to reported earnings. However, the free cash flow to net income ratio suggests room for improvement in cash conversion efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	672.80M	672.80M	668.80M	689.70M	593.40M	574.30M
Gross Profit	672.80M	672.80M	178.70M	239.30M	226.00M	232.20M
EBITDA	85.10M	93.70M	73.70M	87.50M	79.80M	82.30M
Net Income	19.30M	19.30M	7.90M	33.30M	40.90M	47.30M
Balance Sheet
Total Assets	899.00M	899.00M	1.03B	1.01B	1.02B	851.00M
Cash, Cash Equivalents and Short-Term Investments	48.00M	48.00M	42.50M	36.30M	38.80M	46.00M
Total Debt	265.90M	265.90M	291.20M	232.10M	223.80M	151.60M
Total Liabilities	423.00M	423.00M	485.00M	440.30M	445.80M	354.40M
Stockholders Equity	475.60M	475.60M	548.20M	569.40M	578.50M	498.10M
Cash Flow
Free Cash Flow	59.90M	48.60M	5.10M	15.20M	-7.80M	38.80M
Operating Cash Flow	73.30M	67.20M	29.80M	50.40M	34.30M	67.50M
Investing Cash Flow	-22.50M	-13.80M	-19.30M	-30.90M	-67.20M	-46.70M
Financing Cash Flow	-44.00M	-46.60M	-2.80M	-18.20M	21.90M	-14.20M

Genus plc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2515.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GNS, the sentiment is Neutral. The current price of 2515 is below the 20-day moving average (MA) of 2636.25, below the 50-day MA of 2515.40, and above the 200-day MA of 1996.64, indicating a neutral trend. The MACD of 22.84 indicates Positive momentum. The RSI at 43.51 is Neutral, neither overbought nor oversold. The STOCH value of 9.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:GNS.

Genus plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	78 Outperform	130.62M	16.63	0.00%	6.28%	0.49%	-9.52%
GNS	71 Outperform	£1.66B	85.89	3.77%	1.27%	0.60%	142.98%
OXB	65 Neutral	712.68M	-14.47	-75.71%	―	43.84%	74.88%
PRTC	56 Neutral	271.65M	7.87	12.90%	―	1231.50%	0.00%
ONT	51 Neutral	1.56B	-10.74	-24.93%	―	22.03%	20.01%
4BB	39 Underperform	130.07M	-9.57	-46.75%	―	84.39%	-41.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Genus plc Corporate Events

Genus Accelerates Chinese Joint Venture for PRRS Resistant Pig Commercialization

Genus plc has announced an accelerated formation of a joint venture with Beijing Capital Agribusiness Co. Ltd in China, focusing on the commercialization of the PRRS Resistant Pig (PRP). The joint venture, 51% owned by BCA and 49% by Genus, aims to strengthen Genus’s market position in China by leveraging local partnerships to achieve regulatory approvals. The transaction, expected to complete in 2026, will provide Genus with significant financial returns, including a gross cash payment and intellectual property royalties, while also allowing for future economic rights and potential shareholder returns. This strategic move is anticipated to enhance Genus’s operations in the Chinese porcine industry, contributing to the efficiency and sustainability of pork production in China.

The most recent analyst rating on (GB:GNS) stock is a Buy with a £25.50 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.

Genus plc Reports Strong Financial Growth and Strategic Advances in 2025

Genus plc reported strong financial performance for the year ending June 30, 2025, with a 5% increase in revenue in constant currency and a 24% rise in adjusted profit before tax. The company achieved significant strategic progress, including FDA approval for its PRRS Resistant Pig gene edit and the formation of a joint venture in China to accelerate growth and commercialization efforts. These developments are expected to enhance Genus’s market positioning and provide substantial growth opportunities, particularly in the porcine industry.

The most recent analyst rating on (GB:GNS) stock is a Buy with a £25.50 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.

Genus plc Updates Share Capital and Voting Rights

Genus plc announced that as of July 31, 2025, its issued share capital consists of 66,037,454 ordinary shares with voting rights, with no shares held in treasury. This update is significant for shareholders as it affects the calculation of their interests under the FCA’s Disclosure Guidance and Transparency Rules, potentially impacting their reporting obligations.

The most recent analyst rating on (GB:GNS) stock is a Buy with a £2940.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.